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ABSTRACT
Adipose tissue stroma contains a population of mesenchymal stem cells (MSC) 
promote new blood vessel formation and stabilization. These adipose-derived stem 
cells (ASC) promote de novo formation of vascular structures in vitro. We investigated 
the angiogenic factors secreted by ASC and discovered that glial-derived neurotrophic 
factor (GDNF) is a key mediator for endothelial cell network formation. It was found 
that both GDNF alone or present in ASC-conditioned medium (ASC-CM) stimulated 
capillary network formation by using human umbilical vein endothelial cells (HUVECs) 
and such an effect was totally independent of vascular endothelial growth factor 
(VEGF) activity. Additionally, we showed stimulation of capillary network formation 
by GDNF, but not VEGF, could be blocked by the Ret (rearranged during transfection) 
receptor antagonist RPI-1, a GDNF signaling inhibitor. Furthermore, GDNF were 
found to be overexpressed in cancer cells that were resistant to the anti-angiogenic 
treatment using the VEGF antibody. Cancer cells in the liver hepatocellular carcinoma 
(HCC), a non-nervous related cancer, highly overexpressed GDNF as compared to 
normal liver cells. Our data strongly suggest that, in addition to VEGF, GDNF secreted 
by ASC and HCC cells, may be another important factor promoting pathological 
neovascularization. Thus, GDNF may be a potential therapeutic target for HCC and 
obesity treatments.
INTRODUCTION
Angiogenesis is responsible for most, if not all, 
blood vessel growth during development and disease 
pathogenesis [1]. This process could be a target for 
combating diseases characterized by either poor 
vascularization or abnormal vasculature. Some diseases, 
such as ischemic chronic wounds in brain and heart, 
are the result of failure or insufficient blood supply and 
could be treated by a local expansion/formation of blood 
vessels, thus bringing new nutrients to the site, facilitating 
repair [2]. In contrast, other diseases like obesity and solid 
tumors, angiogenesis is required for their growth and 
metastasis by supplying nutrients, oxygen, and removing 
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wastes as well as transporting cancer cells to a distant site 
[3, 4]. Tumor vessels also have the theoretical potential 
for developing acquired resistance to drugs to escape 
therapy [5]. Therefore, angiogenesis inhibition prevents 
the formation of new blood vessels, thereby stopping or 
slowing the expansion of adipose tissue in obesity as well 
as the growth or spread of tumors.
Mesenchymal stem cells (MSC) isolated from 
many different tissues all secrete potent proangiogenic 
factors [6]. Adipose-derived stem cells (ASC) are 
pluripotent MSC in the stromal or non-adipocyte 
fraction of the adipose tissue and were demonstrated to 
exhibit differentiation into endothelial as well as smooth 
muscle-like cells and induce new neovascularization 
of ischemic tissues [7–10]. Recently, it was reported 
that recruitment of endogenous ASC from fat tissue is 
particularly associated with increased vascularization and 
adipogenesis accompanied by proliferation of malignant 
cells [11]. Like cancer cells [12–14], ASC secret many 
angiogenic factors including VEGF, hepatocyte growth 
factor (HGF) and fibroblast growth factor (FGF), which 
stimulate neovascularization in vivo and vascular 
network formation in vitro [6, 10] and widely used to 
establish an in vitro angiogenic model [10]. Generally 
speaking, many growth factors involved in angiogenesis, 
including VEGF, PDGF, and FGF, are secreted by ASC [6, 
10, 15, 16] and cencer cells [12-14, 17, 18]. VEGF is well 
accepted as the major angiogenic factor for both stem cells 
and cancer cells, and three classes of agents that mainly 
target VEGF have been developed in research or clinical 
practice: monoclonal antibodies, VEGF decoy receptors, 
and small molecule tyrosine kinase inhibitors (TKIs). Anti-
angiogenic agents are currently used in the monotherapy 
or in combination with cytotoxic chemotherapy or 
radiation for treating cancers [19] and also proposed for 
obesity treatment [20]. However, despite much effort, 
major concerns remain in using the antiangiogenic 
approach for cancer treatment, including tumor resistance 
due to overcompensation from the parallel growth 
factors or signaling pathways. In the obesity treatment, 
although several angiogenesis inhibitors could markedly 
reduce body weight [21], inhibition of VEGF-dependent 
angiogenesis might not play an important role in these 
cases since it had been shown that anti-VEGF treatment 
did not induce significant weight loss in mice [22]. Further 
research is therefore necessary to improve the existing 
treatments by combinations of these agents simultaneously 
targeting multiple anti-angiogenic pathways for cancer and 
obesity treatments.
Glial cell line-derived neurotrophic factor (GDNF) 
is a member of the transforming growth factor-beta 
superfamily and possesses potent neuroprotective effect on 
a variety of neuronal damage [23, 24]. Topical application 
and intracerebral administration of GDNF significantly 
decreased the size of ischemia-induced brain infarction 
and the number of TUNEL-positive neurons with 
suppression of the apoptotic pathways [25]. Additionally, 
it was also demonstrated that GDNF might promote vessel 
integrity in cultured neonatal rabbit explants containing 
the nephrogenic zone of the kidney [26] and assumed 
GDNF was possibly involved in angiogenesis through the 
VEGF pathway [26]. However, the actual mechanism by 
which GDNF and the RET receptor (the rearranged during 
transfection (RET) proto-oncogene product, a tyrosine 
kinase receptor) that is involved in GDNF signaling 
induce angiogenesis and whether this process involves 
VEGF has not been determined. The mRNA for GDNF 
was recently detected in ASC by RT-PCR; however, 
it was not determined if these cells express functional 
GDNF protein [27]. In this study we demonstrate that 
active GDNF protein is indeed expressed by ASC in 
culture and potently promotes angiogenesis in vitro. Since 
ASC potentially promote carcinogenesis by homing to 
tumors, where they promote angiogenesis [11, 28, 29], we 
investigated whether and how GDNF contributes to new 
blood vessel formation, either alone or in combination 
with VEGF. Additionally, since angiogenesis in cancer 
development may be stimulated by both adipose and 
cancer cells in a similar way [30], we further investigated 
whether GDNF could also be expressed and secreted by 
liver hepatocellular carcinoma (HCC) cells that are non-
nervous and not response to anti-VEGF treatments. In 
this study, we discovered that GDNF was present in HCC 
but not in surrounding normal liver tissues. Together, the 
findings of GDNF expression by ASC and HCC cells 
suggest new potential therapeutic targets for cancer and 
obesity treatments.
RESULTS
ASC-CM markedly stimulated the capillary-
like tube formation of HUVEC in matrigel and 
VEGF in the ASC-CM played a significant role 
in this process
To investigate the angiogenic effects of ASC-CM 
on tube formation by endothelial cells, we conducted in 
vitro experiments using HUVECs which form tube-like 
structure after 48 hours cultures in Matrigel. ASC-CM 
stimulated tube formation in a dose-dependent manner 
(DMEM: 157.2 ± 50.5 mm/cm2, 25% ASC-CM: 246.8 
± 77.5 mm/cm2, 50% ASC-CM: 869.8 ± 90.4 mm/
cm2, 100% ASC-CM: 964.1 ± 71 mm/cm2, p< 0.001) 
(Figure 1). Since previous evidence showed that VEGF 
was a key player in the tube formation, we examined how 
much VEGF in the ASC-CM was involved in ASC-CM-
stimulated tube formation. We measured the VEGF level 
in the ASC-CM by using ELISA and detected a significant 
level of VEGF (0.91 ± 0.05 ng/ml) that was present in 
the ASC-CM. As expected, capillary network formation 
was diminished by 60% through inactivation of VEGF in 
the ASC-CM (686 ± 107 mm/cm2 vs. 263 ± 71 mm/cm2, 
p<0.001) (Figure 4).
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GDNF in the ASC-CM also promoted capillary 
network formation at a similar degree to VEGF 
did
In addition to the many angiogenic factors 
previously shown to be produced by ASC, these cells also 
secreted a significant level of GDNF (23.6 ±1.35 ng/ml) 
that was detected by ELISA. Neutralization of GDNF 
using an inactivating antibody abolished the effect of 
ASC-CM on endothelial network formation at a similar 
degree as inactivation of VEGF did (764 ± 134 mm/cm2 
vs. 240 ± 108 mm/cm2, p<0.01, Figure 2) (Figure 2A). 
Additionally, addition of recombinant GDNF individually 
promoted capillary network formation in a dose fashion 
(0: 157 ± 38 mm/cm2, 1ng/ml GDNF: 168 ± 38 mm/cm2, 
10ng/ml GDNF: 351 ± 112 mm/cm2, 100ng/ml GDNF: 
442 ± 171 mm/cm2) (Figure 2B). For further confirmation, 
10 ng/ml of recombinant GDNF was added to ASC-CM 
that endogenous GDNF had been depleted by using 
immunoprecipitation with an anti-GDNF antibody and 
the mixture dramatically recovered the tube formation 
activity (240 ± 108 mm/cm2 vs. 544.43 ± 110 mm/cm2, 
p< 0.01) (Figure 3). Interestingly, addition of exogenous 
VEGF at either 1 or 10 ng to GDNF-depleted ASC-CM 
also re-established network formation activity (240 ± 108 
mm/cm2 vs. 542 ± 130 mm/cm2 or 601 ± 125 mm/cm2, p< 
0.01) (Figure 3), indicating levels of endogenous VEGF 
in GDNF-depleted ASC-CM was not enough to stimulate 
angiogenesis, but could be helped by addition of either 
exogenous GDNF or VEGF.
Capillary network formation stimulated by 
GDNF was independent of VEGF activity
Since a previous study suggested that GDNF 
may induce angiogenesis through the VEGF pathway, 
we investigated whether GDNF was able to induce 
angiogenesis in the absence of VEGF. We pre-incubated 
1 ml ASC-CM with 2 ml VEGF neutralizing antibody 
at the concentration of 500 mg/ml (Abcam, Cambridge, 
Figure 1: ASC-CM stimulated capillary network formation by HUVEC in Matrigel. HUVECs suspended in Matrigel 
were subjected to different doses of ASC-CM treatments or DMEM and analyzed for capillary network formation after 48 hours. 
A. Representative images demonstrating capillary network formation of HUVECs in Matrigel media. a: 100% DMEM; b: 25% ASC-CM in 
DMEM; c: 50%ASC-CM in DMEM; d: 100 % ASC-CM. B. Capillary networks were stained and analyzed as described in Methods. Data 
of tube length represent mean ± SD of three independent experiments. N=3, *** p<0.001 compare with 100% DMEM.
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MA) for 30 min to remove endogenous VEGF activity 
and demonstrated that exogenous VEGF was not able to 
induce capillary network formation in this media (263 
± 71 mm/cm2 vs. 269 ± 89 mm/cm2 or 274 ± 85 mm/
cm2) by adding external VEGF (1 or 10 ng/ml) into this 
VEGF-neutralized ASC-CM. Interestingly, addition of 
recombinant GDNF into this VEGF-neutralized ASC-CM 
even at as low as 1 ng/ml still significantly stimulated 
capillary network formation (263 ± 71 mm/cm2 vs. 568 ± 
119 mm/cm2, P<0.01) (Figure 4). It should be noted that 
in Figure 3, we used the immunoprecipitation method 
and the anti-GDNF antibody was removed before adding 
ASC-CM. In contrast, in Figure 4, we used the VEGF 
neutralizing antibodies to neutralize the VEGF. The 
addition of GDNF at 1 ng/ml into ASC-CM pretreated 
with the excess amount of VEGF antibody was able to 
stimulate HUVECs tube formation, indicating that GDNF 
was able to exert the angiogenic function without the 
presence of VEGF activity. For further confirmation, we 
showed that treatment of HUVEC with 10 ng/ml GDNF 
did not stimulate VEGF secretion (Figure 5A, 4.98 ± 1.54 
pg/ml VS. 5.49 ± 2.92 pg/ml). Additionally treatment of 
ASC with 10 ng/ml GDNF did not affect VEGF secretion 
(Figure 5B, 0.91 ± 0.05 ng/ml vs. 0.85 ± 0.04 ng/ml) and 
VEGF did not modulates GDNF expression in ASC (23.6 
±1.35 ng/ml vs. 2.48 ± 1.52 ng/ml).
Inhibition of RET receptor, a downstream factor 
of the GDNF signaling pathway blocked GDNF–
induced capillary network formation
We used RPI-1 to further confirm GDNF directly 
induced capillary network formation. RPI-1 is a 
competitive inhibitor of the ATP-dependent RET kinase 
receptor that is involved in GDNF signaling [31, 32]. As 
expected, addition of the RPI-1 potently blocked capillary 
network formation induced by GDNF, indicating that 
activation of the RET co-receptor was required for the 
Figure 2: GDNF in ASC-CM and recombinant protein stimulated the network formation of HUVECs in Matrigel. 
A. GDNF antibody inhibited ASC-CM-stimulated capillary network formation. Representative images demonstrating the tube network 
formation of HUVECs in Metrigel. a: 100% DMEM; b: 50% ASC-CM c: 50% ASC-CM+GDNF antibody. The tube length in three wells of 
each treatment was compared to those without ASC-CM treatments (total length ± SD). **: p<0.01, ***: p<0.001, compared with the group 
of 100% DMEM. B. GDNF stimulated the network formation of HUVECs in Matrigel. Representative images demonstrating the tube 
network formation of HUVECs in Matrigel. a: DMEM; b: DMEM+ 1ng/ml GDNF; c: DMEM+ 10ng/ml GDNF; d: DMEM+ 100ng/ml 
GDNF. Analysis was performed at 48 hours following ASC-CM treatments. Data of tube length represent mean ± SD of three independent 
experiments. N=3, *: p<0.05, compared with the group of DMEM.
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angiogenic properties of GDNF (Figure 6). In contrast, 
RPI-1 did not affect VEGF-induced capillary network 
formation.
GDNF is overexpressed in human HCC
At last, we investigated whether GDNF, as an 
independent angiogenic factor, was also secreted by HCC 
cells since Bevacizumab, the VEGF antibody could not be 
used to effectively treat HCC [33]. An immunohistological 
analysis of human HCC specimens was performed by using 
the anti-GDNF antibody and our results revealed in 42 
patients, there were dramatically increased expression levels 
of the GDNF in HCC, as compared to normal liver tissue 
from same patient in all tested specimens (Figure 7A, 69.4 
± 5.4% VS 5.3 ± 1.3%, p<0.001). The Western blot was also 
used to confirm that the expression of GDNF in HCC tissue 
was significantly higher than normal liver tissue (0.64±0.22 
VS 0.31±0.11, p<0.05) (Figure 7B). This finding further 
supports that even blockade of VEGF angiogenic function, 
highly expressed GDNF in HCC cells may continuously 
stimulate HCC angiogenesis and progression.
Figure 3: Addition of GDNF or VEGF back to ASC-CM depleted of GDNF was able to recover ASC-CM-induced tube 
network formation of HUVECs. A. Representative images demonstrating the tube network formation of HUVECs in Metrigel. a: 50% 
ASC-CM; b: 50% ASC-CM+ anti-GDNF (IP); c: 50% ASC-CM+ anti-GDNF (IP)+ 1ng/ml GDNF; d: 50% ASC-CM+ anti-GDNF (IP)+ 
10ng/ml GDNF; e: 50% ASC-CM+ anti-GDNF (IP)+ 1ng/ml VEGF; f: 50% ASC-CM+ anti-GDNF (IP)+ 10ng/ml VEGF. B. Analysis was 
performed at 48 hours following ASC-CM treatments. Data of tube length represent mean ± SD of three independent experiments. N=3, 
*: p<0.05, ***: p<0.001, compared with the group of ASC-CM, ##: p<0.01, compared with the group of ASC-CM+ anti-GDNF (IP).
Oncotarget36834www.impactjournals.com/oncotarget
DISCUSSION
ASC have been previously demonstrated to be 
involved in angiogenesis and vascular formation through 
direct contact with endothelial cells and by provision of 
angiogenic growth factors, such as VEGF, HGF, platelet-
derived growth factor (PDGF) and metalloproteinase [10, 
15]. Each of these factors was shown to be important for 
de novo vessel formation in vitro [15]. However, ASC 
secrete many other factors with demonstrated or potential 
pro-angiogenic activities; therefore, it is possible that 
other factors present in ASC-CM could influence vessel 
growth, especially under pathophysiological conditions. 
Certainly, FGF that is key factor for stem cell survival 
has been considered as a major factor in cancer 
angiogenesis [34].
ASC has recently been widely investigated in 
angiogenesis because it can be used to treat brain and 
heart ischemia partially through recovering blood supply 
into ischemic areas [15, 35, 36]. Additionally, fat tissues, 
particularly white fat tissues, in addition to involving 
in obesity development, were found to be involved in 
carcinogenesis and related angiogenesis [34]. Factors 
secreted from ASC were shown to be definitely involved in 
Figure 4: Addition of GDNF into ASC-CM pretreated with the excess amount of the VEGF antibody was able to 
stimulate HUVECs tube formation. A. Representative images demonstrating the tube network formation of HUVECs in Metrigel. a: 
50% ASC-CM; b: 50% ASC-CM+ anti-VEGF; c: 50%ASC-CM+ anti-VEGF+ 1 ng/ml GDNF; d: 50% ASC-CM+ anti-VEGF+ 10 ng/ml 
GDNF; e: 50% ASC-CM+ anti-VEGF+ 1 ng/ml VEGF ; f: 50% ASC-CM + anti-VEGF+ 10 ng/ml VEGF. B. Analysis was performed at 
48 hours following ASC-CM treatments. Data of tube length represent mean ± SD of three independent experiments. N=3, ***: p<0.001, 
compared with the group of ASC-CM; ##: p<0.01, compared with the group of ASC-CM+ anti-VEGF.
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building a microenvironment that enhanced angiogenesis 
in cancer [37–39]. Therefore, understanding the function 
of those factors that play key role in angiogenesis is 
necessary for effective obesity, cancer and ischemic injury 
treatment.
Blocking angiogenesis in cancer development is 
an attractive therapeutic treatment not only because 
it could be used to treat a wide spectrum of cancers, 
but also provides a new class of treatments with low-
toxicity/side effects [40]. Bevacizumab, however, a 
monoclonal antibody targeting VEGF used clinically 
to treat cancers has a limited number of cancer targets 
and low efficacy, which limits its range of usefulness. 
Antiangiogenic therapy for cancer has met with a 
number of hurdles on its way to becoming an option 
for cancer therapy [41–43]. Multiple clinic trial have 
demonstrated that the benefit of VEGF-targeted therapy 
is variable and depends, in part, on the tumor type, 
stage and treatment history [44]. The primary concern is 
whether other targets that promote cancer angiogenesis 
can compensate for VEGF depletion. Reports indicated 
that FGF might induce angiogenesis and its activity 
must also be neutralized to fully treat cancer [38, 45]. 
However, the microenvironment for angiogenesis 
is complicated and may still require identifying and 
targeting other factors that may independently induce 
cancer angiogenesis. Recently, angiogenesis inhibitors 
have also been suggested for obesity treatments since 
angiogenesis in obesity provides new blood vessels are 
able to bring nutrients and oxygen to expand fat tissue 
[20]. However, angiogenesis in obesity is through a 
complex mechanism since anti-VEGF treatment failed 
to induce significant weight loss [22]. Here, we used 
ASC as an investigative model since they have been 
demonstrated to contribute to angiogenesis in both 
cancer and ischemic tissues. By using conditioned 
media comprised of factors secreted by these cells, 
we clearly demonstrated that both VEGF and 
GDNF played significant roles in ASC-CM-induced 
angiogenesis. Interestingly, GDNF, which is usually 
assumed to function as a neuroprotective factor, was 
able to induce angiogenesis independently from the 
VEGF pathway. Ret-1, a specific GDNF receptor, 
specifically mediates GDNF- but not VEGF-induced 
Figure 5: A, B. GDNF treatments did not stimulate VEGF secretion in HUVECs and ASC. 24-hour treatments of GDNF at 10 ng/ml did 
not affect VEGF production in HUVECs and ASC. C. VEGF did not affect GDNF production in ASC. 10 ng/ml VEGF treatments did not 
affect GDNF production in ASC. Data represent mean ± SD of three independent experiments. N=3, ***: p<0.001, compared with the 
group of DMEM.
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angiogenesis. Additionally, GDNF did not affect VEGF 
expression and, furthermore, blocking VEGF activity 
did not inhibit GDNF-induced angiogenesis. All of 
these data strongly suggest that GDNF induces new 
vessel growth independently of the VEGF angiogenesis 
pathway. Interestingly, Ret was reported to mediate 
neurturin (NRTN)-, a member of the GDNF family of 
ligands (GFL), induced phosphorylation of the signal 
transducers and activators of transcription 3 (STAT3) 
[46]. STAT3 played a critical role in oncogenesis and 
angiogenesis [47, 48]. Therefore, STAT3 signaling is 
possibly involved in GDNF-induced angiogenesis . 
Additionally, GDNF, was strongly overexpressed in 
human liver cancer cells, indicating solely blocking 
VEGF in these cancers would not be effective 
in preventing cancer progression and metastasis. 
Therefore, it should be very interesting to investigate 
how GDNF is involved in cancer and obesity 
pathogenesis.
Since GDNF is clearly another independent key 
player in angiogenesis, induced by adipose stem cells 
and cancer cells, it is necessary to further investigate 
its downstream pathways as this factor may closely be 
involved in angiogenesis in cancer, obesity, and ischemia 
injury. It should be noted that high doses of VEGF 
appeared to replace GDNF angiogenic activity when 
GDNF had been neutralized in ASC-CM, indicating 
without GDNF, VEGF could also independently induce 
angiogenesis. The combination of inhibiting both factors 
would be required for effective therapy on angiogenesis.
Figure 6: RPI-1, the inhibitor of the GDNF receptor (RET), affects GDNF, but not VEGF, induced HUVECs tube 
formation. A. Representative images demonstrating the tube network formation of HUVECs in Matrigel. a: control: DMSO; b: 10 ng/
ml GDNF; c: 10 ng/ml GDNF+ 1.5 μM RPI-1; d: DMEM+ 10ng/ml VEGF; e: DMEM+ 10ng/ml VEGF+ 1.5 μM RPI-1. B. Analysis was 
performed at 48 hours following ASC-CM treatments. Data of tube length represent mean ± SD of three independent experiments. N=3, *: 
p<0.05, ***: p<0.001, compared with the control group of DMSO.
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MATERIALS AND METHODS
Isolation and culture of human ASC
Human subcutaneous adipose tissue samples, 
obtained from elective lipoaspiration/liposuction 
procedures were minced before digesting in 1 mg/ml 
Collagenase Type I solution (Worthington Biochemical 
Corporation, Lakewood, NJ) under gentle agitation for 
1 hour at 37° C. The digested mixture was diluted with 
50 ml culture medium (DMEM, high glucose, 10% 
FBS) and centrifuged at 200g for 5 minutes to separate 
the stromal cell fraction (pellet) from adipocytes. The 
supernatant was removed and the cellular pellet was 
re-suspended in 20 ml of fresh medium (DMEM/10% 
FBS), and then serially filtered through 250μm Nitex 
03-250/50 cloth (Sefar American Inc., Depew, NY) and 
a 100μm cell strainer (BD Biosciences, Franklin Lakes, 
NJ) to remove debris. The filtrate was again centrifuged 
at 200 g for 5 minutes. The pellet containing ASC was 
treated with red blood cell lysis buffer for 5 minutes at 
37°C and then pelleted at 300g for 5 minutes. The cell 
pellets were re-suspended in the EGM-2MV medium 
(Lonza, Allendale, NJ). ASC were plated in an uncoated 
T75 tissue culture flask at a density of 4 x106 cells/
cm2 and incubated in a humidified chamber at 37oC in 
an atmosphere of 5% CO2. After overnight culture, the 
medium was replaced with Endothelial Growth Medium 
2-MicroVascular (EGM2-MV, Lonza, Allendale, NJ). 
The Indiana University ethics committee approved the 
experiments and all informed consent was obtained from 
all subjects. All methods were performed in accordance 
with approved guidelines.
Collection of ASC conditioned media (ASC-CM) 
and human umbilical vein endothelial cells 
conditioned media (HUVEC-CM)
Human ASC were cultured to confluence in 100mm 
culture dishes containing EGM2-MV medium, and each 
dish was rinsed and replenished with 5 ml Dulbecco’s 
Modified Eagle’s Medium (DMEM, Invitrogen, Grand 
Island, NY) for 24 hours. Media were collected and 
centrifuged at 3000 g and stored at -80oC until use. 
Conditioned medium from mature human umbilical vein 
endothelial cells (HUVEC-CM) was obtained in parallel 
Figure 7: GDNF was overexpressed in the HCC as compared to the normal liver tissue. A. Immunohistological studies 
by using GDNF antibodies were performed in the HCC and normal liver tissue. a: normal liver tissue b: HCC. B. Western blot analysis 
of GDNF expression in normal liver tissue and HCC. Band intensities by western blot were quantified by normalizing to β-actin. N=42, 
*: p<0.05, ***: p<0.001, compared with control group of normal liver tissue.
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and applying the same protocol, respectively. Growth 
factor-free DMEM with 1% FBS was used as control 
medium in all experiments.
Quantification of GDNF and VEGF by ELISA
Levels of GDNF and VEGF in ASC-CM and 
HUVEC-CM were measured using an enzyme-linked 
immunosorbent assay (ELISA) kit, Human VEGF 
Quantikine Elisa kits (R&D system, Minneapolis, MN), 
according to the manufacturer’s instructions [49]. All 
samples and standards were measured in duplicate.
Depletion GDNF by immunoprecipitation (IP)
1 ml ASC-CM was incubated overnight at 4 °C 
with 2 μl anti-GDNF antibody (500μg/ml) (Abcam, 
Cambridge, MA). Protein A-agarose was added, and a 
second overnight incubation was performed, followed by 
centrifuging.
Matrigel assay
Ninety six–well plates were coated with 100 μl per 
well of growth factor-reduced Matrigel (BD Biosciences, 
Franklin Lakes, NJ). Plates were incubated overnight 
at 4oC then at 37oC for 2 hours. HUVECs at passage 6 
(104 cells/well) in 100 μl of different medium and were 
cultured at 37oC with 5% CO2 for 1hour, after HUVECs 
touched the Matrigel, then changed different medium, and 
monitored after 48hours, took pictures by microscopy. 
Data analyzed by MetaMorph7.0 IMAGE Analysis 
Software [50].
Immunocytochemistry of GDNF in HCC and 
liver cirrhosis tissue
We performed immunohistochemistry for GDNF 
in 42 cases of HCC and liver cirrhosis tissue (From 
Peking University People’s Hospital General Surgery 
Department, Beijing, China). The Peking University 
People’s Hospital ethics committee approved the 
experiments and all informed consent was obtained 
from all subjects. All methods were performed in 
accordance with approved guidelines. After fixation 
with formaldehyde and endogenous peroxidase activity 
quenching, sections were incubated with bovine serum 
albumin for 1 hour, then, they were incubated with 
primary antibody for GDNF (1:500; Abcam, Cambridge, 
MA) overnight at 4 °C. On the next day, we treated the 
sections with mouse monoclonal biotinylated secondary 
antibody (1:200; Cell Signaling, Danvers, MA) for 2 
hours at room temperature. Imumuoreactivities were 
developed in horseadish peroxidase-streptavidin-biotin 
complex solution (Vectastatin ABC kit; Vector Labs, 
Burlingame, CA) for 30 minutes and then incubated with 
diaminobenzidine (DAB; Sigma-Aldrich, St. Louis, MO). 
Negative controls were included by omitting the primary 
antibody. The positively stained cells were identified by 
their morphology, and the staining intensity was measured 
by Image pro 6 [51]. GDNF was evaluated in the zone of 
GDNF- positive areas in five sections per HCC or liver 
tissue.
Quantitative western blot assay
The protein extract of HCC tissues separated by 
SDS-PAGE were transferred to PVDF membrane. The 
blots were probed with GDNF antibody (1:500, Abcam, 
Cambridge, MA, USA), followed by a secondary antibody 
conjugated with horseradish peroxidase (1:5000) and 
visualized by utilizing enhanced chemiluminescence. 
β-actin was also assayed as loading controls by using its 
antibody (1:1000). Band intensities were quantified and 
results were reported as a ratio of GDNF to β-actin [52].
Statistical analysis
Unless indicated, otherwise, data are given as means 
± SD; with the number of determinations (n) representing 
separate experiments carried out independently using 
triplicate samples. Data were evaluated using one-way 
ANOVA and a P value of less than 0.05 was considered 
significant.
CONCLUSION
GDNF alone or present in ASC-CM stimulated 
capillary network formation by HUVECs and this effect 
was totally independent of VEGF activity. Additionally, 
the stimulation of capillary network formation by GDNF 
could be blocked by the GDNF Ret receptor antagonist 
RPI-1. We also revealed that GDNF was overexpressed 
in HCC cells that were resistant to the anti-angiogenic 
treatment using VEGF antibody. Our data strongly 
suggest that, in addition to VEGF, GDNF secreted by 
ASC, and possibly non-nervous tumors such as HCC 
cells, is another important factor promoting pathological 
neovascularization. Thus, GDNF is a potential therapeutic 
target for cancer and obesity.
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